Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer

BACKGROUND: Gemcitabine/cisplatin (GP) resistance displays a negative role in treating advanced and metastatic non-small cell lung cancer (NSCLC). Several studies found that the association existed between platelets and cancer antigen 125 (CA125) with anticancer drugs. But the exact correlation betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liang, Li, Yiming, Yu, Tingting, Wang, Zeng, Zhou, Chenxi, Xing, Wenxiu, Xu, Gaoqi, Tong, BingLei, Zheng, Yingchao, Zhou, Jie, Huang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/
https://www.ncbi.nlm.nih.gov/pubmed/30498189
http://dx.doi.org/10.12659/MSM.911125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284361/
https://www.ncbi.nlm.nih.gov/pubmed/30498189
http://dx.doi.org/10.12659/MSM.911125

Ejemplares similares